Revelation Biosciences, Inc.
REVB
$3.40
$0.061.80%
| Weiss Ratings | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.72 | |||
| Price History | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.58% | |||
| 30-Day Total Return | -19.81% | |||
| 60-Day Total Return | -49.40% | |||
| 90-Day Total Return | -74.46% | |||
| Year to Date Total Return | -67.66% | |||
| 1-Year Total Return | -93.19% | |||
| 2-Year Total Return | -99.59% | |||
| 3-Year Total Return | -99.98% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -94.51% | |||
| 52-Week Low % Change | 4.70% | |||
| Price | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $60.80 | |||
| 52-Week Low Price | $3.19 | |||
| 52-Week Low Price (Date) | Feb 26, 2025 | |||
| 52-Week High Price (Date) | Jun 24, 2024 | |||
| Valuation | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.74M | |||
| Enterprise Value | -4.75M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -268.13 | |||
| Earnings Per Share Growth | -35.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.34 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.40 | |||
| Enterprise Value/EBITDA (TTM) | 0.56 | |||
| Enterprise Value/EBIT | 0.56 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 167.50K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 800 3717 | |||
| Address | 4660 La Jolla Village Drive San Diego, CA 92122 | |||
| Website | www.revbiosciences.com | |||
| Country | United States | |||
| Year Founded | 2020 | |||
| Profitability | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -50.98% | |||
| Return on Equity | -- | |||
| Income Statement | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -8.52M | |||
| EBIT (TTM) | -8.55M | |||
| Net Income (TTM) | -15.52M | |||
| Net Income Avl. to Common (TTM) | -15.52M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 14.72% | |||
| EPS Diluted (TTM) | -268.13 | |||
| EPS Diluted Growth (Q YOY) | 91.55% | |||
| Balance Sheet | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.54M | |||
| Cash Per Share (Q) | $39.05 | |||
| Total Current Assets (Q) | 6.66M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.67M | |||
| Current Ratio (Q) | 1.638 | |||
| Book Value Per Share (Q) | $9.97 | |||
| Total Assets (Q) | 6.74M | |||
| Total Current Liabilities (Q) | 4.07M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 4.07M | |||
| Total Common Equity (Q) | 2.67M | |||
| Cash Flow | REVB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -36.90K | |||
| Cash from Financing (TTM) | 9.16M | |||
| Net Change in Cash (TTM) | -7.45M | |||
| Levered Free Cash Flow (TTM) | -6.52M | |||
| Cash from Operations (TTM) | -16.58M | |||
